A 2025 Phase 2 clinical trial funded by Eli Lilly that enrolled 263 adults who were overweight or obese without diabetes found that once-weekly injectable eloralintide produced dose-dependent weight loss of 9.5% to 20.1% of body weight after 48 weeks, compared with a 0.4% mean weight change in the placebo group.
January 01, 2025
high
temporal
Primary efficacy results from a Phase 2 trial of eloralintide
A 2025 Phase 2 clinical trial of eloralintide reported that treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation in adults who were overweight or obese without diabetes.
January 01, 2025
high
temporal
Cardiometabolic and inflammatory secondary outcomes reported in the Phase 2 trial
Eloralintide is a selective amylin receptor agonist that mimics the pancreatic hormone amylin and is intended to slow gastric emptying, reduce appetite, and help control postprandial blood glucose; this mechanism differs from GLP-1 receptor agonists, which mimic the gut hormone GLP-1.
high
descriptive
Pharmacological mechanism of action for eloralintide compared with GLP-1 receptor agonists